Latest retatrutide data, November 2026: knee pain and sleep apnea
Retatrutide is in the conversation again this month. Within two weeks, Eli Lilly took Phase 3 clinical trial results for retatrutide to two major scientific meetings in the United States. The focus went beyond body weight to knee pain from osteoarthritis and sleep apnea, two complaints that often come with excess weight.
- 5 November 2026
- Lilly announced retatrutide data for ACR Convergence 2026, Orlando, 6 to 11 November.
- 8 and 10 November 2026
- TRIUMPH-4 and TRIUMPH-1 knee pain results were presented at ACR Convergence.
- 14 November 2026
- Lilly announced data for ObesityWeek 2026, Washington D.C., 14 to 17 November.
- 15 November 2026
- Sleep apnea results were presented in an ObesityWeek oral session.
- Source
- Official Eli Lilly and Company releases via PR Newswire, 5 and 14 November 2026.
Knee pain: TRIUMPH-4 and TRIUMPH-1 results
Both studies enrolled adults with knee osteoarthritis pain who also had obesity or overweight. Pain was measured with the WOMAC pain subscale, a standard questionnaire for knee and hip joint complaints. The average pain score at the start of the studies was 6.0.
In TRIUMPH-4, which ran for 68 weeks, the pain score fell by up to an average of 4.5 points, or 75.8%. Lilly also reported that more than 1 in 8 participants receiving retatrutide had no knee pain at the end of the study. These results were presented in a plenary session on 8 November 2026.
In TRIUMPH-1, which ran for 80 weeks with three weekly dose levels, the pain score fell by up to an average of 4.3 points, or 73.1%, and more than 1 in 6 participants had no knee pain at the end of the study. These results appeared as a poster on 10 November 2026. According to the release notes, the percentage figures in both studies were calculated in a follow-up analysis after the studies ended.
Sleep apnea: results presented at ObesityWeek
Obstructive sleep apnea makes breathing stall repeatedly during sleep. It is measured with the apnea-hypopnea index (AHI), the number of breathing disruptions per hour of sleep. Lilly presented two groups of adults with moderate-to-severe sleep apnea.
| Study | Participants | Reduction in AHI |
|---|---|---|
| TRIUMPH-1 | Obesity or overweight | Up to an average of 36.1 events per hour (60.6%) |
| TRIUMPH-2 | Obesity or overweight, with type 2 diabetes | Up to an average of 28.4 events per hour (48.1%) |
Why one molecule reaches so many conditions
Retatrutide acts on three hormone receptors at once: GIP, GLP-1, and glucagon. The first two regulate fullness and blood sugar, while glucagon helps push the body to burn energy. This combination is why it is often called a triple agonist. The full explanation is in the article on retatrutide vs tirzepatide.
Less body weight also eases the load on the knee joints and the airway, so it makes sense that researchers track these complaints specifically. Beyond knees and sleep apnea, the retatrutide Phase 3 program also covers type 2 diabetes, chronic low back pain, heart and kidney health, and metabolic dysfunction-associated steatotic liver disease (MASLD). Every person responds differently, and the figures above are study group averages.
If you follow retatrutide news in Indonesia, the piece on retatrutide in Indonesia covers how to read the headlines around this molecule, and retatrutide with cagrilintide explains why the two are often discussed together.
Retatrutide in the Peptivia catalog
Peptivia offers Retatrutide and the Retatrutide with Cagrilintide combination, with notes on how they work and the available vial sizes. You can browse other metabolism products in the Peptivia catalog. Once you have read the product information carefully, you can place your order through the official Peptivia WhatsApp, and our team is happy to answer your questions.
